Mitsui Toatsu Chemicals, Incorporated

Japanese Foundation for Cancer Research

Teijin Limited

Ajinomoto Co., Ltd.

Eisai Company, Limited

Tanabe Seiyaku Company, Limited

Toudai Tlo, Ltd.

Cancer Institute, Japanese Foundation for Cancer Research

Oncotherapy Science, Incorporated

Takashi Tsuruo

Tsuneji Suzuki

Nobuyuki Fukazawa

Kengo Otsuka

Makoto Odate

Wakao Sato

Naoki Tsuchiya

Naoki Hase

Susumu Takeuchi

Takumi Takeyasu

Takao Yamori

Yoshio Sakurai

Akihiro Tomida

Koji Ohsumi

Haruo Sugano

Chikahiko Eguchi

Hirofumi Hamada

Akira Kamimura

Kazuo Shinya

Saburo Sone

Hirozumi Eto

Hisashi Shinkai

Hae-Ryong Park

Kouzou Toyota

Masahiro Fukuoka

The present inventors intended to search for substances that can regulate the expression of a molecular chaperone, GRP78, using the expression of GRP78 as an indicator. As a result, a novel tetronic acid derivative, versipelostatin compound (also known as JL68) shown in formula (I) having the activity of suppressing GRP78 expression was isolated from the metabolite ofstrain 4083-SVS6. Versipelostatin can be obtained from the culture supernatant by culturing the above-mentionedstrain 4083-SVS6 

Tetronic acid derivative

The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.&#x2003;

Anthranilic acid derivative

The present invention relates to an anthranilic acid derivative expressed by the following formula (1) or the following formula (2), or its pharmacologically permissible salt or solvate.

Anthranilic acid derivatives

Heterocyclic compounds useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells are disclosed, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative.

Quinoline derivatives

Agents against drug-resistant tumor cells comprising a 1,4-dihydropyridine derivative represented by the following formula (I): ##STR1## wherein R.sup.1 is an aryl group which may be substituted;

1,4-dihydropyridine-4-aryl-2,6-dimethyl-3,5-dicarboxylates useful as

Novel heterocyclic compounds, which are represented by the following general formula, useful as anticancer drug potentiaters having a potentiating effect on the incorporation of anticancer drugs into cancer cells, the compounds each synthesized by, for example, reacting a epoxy compound obtained by reacting a heterocyclic compound with an epihalogenohydrin, with an amine derivative.

Heterocyclic compounds and anticancer-drug potentiaters conaining them

Monoclonal antibodies are disclosed that may be produced by hybridomas obtained by fusing a mouse spleen cell immunized with an ADRIAMYCIN.RTM.-resistant human tumor cell and a mouse myeloma cell and which inhibit selectively the growth of cancer cells possessing pleiotropic drug resistance or enhance their sensitivity to said drug.

Monoclonal antibody for use in drug resistant cancers and production

5-((3,4-dimethoxyphenetyl)methylamino)- 2-(3,4-dimethoxy-phenyl)-2-isopropylvaleronitrile or a pharmaceutically acceptable salt thereof is effective to prevent metastasis of cancer.

Antimetastatic agent

An agent for enhancing antitumor activity of antitumor agents comprising as the active ingredient diltiazem or a pharmaceutically acceptable acid addition salt thereof, an antitumor composition comprising the diltiazem or an acid addition salt thereof and a conventional antitumor agent, and further a method for treating tumors by administering diltiazem or an acid addition salt thereof together with a conventional antitumor agent in oral or parenteral route to patients suffering from various tumors. Said active diltiazem or a salt thereof is effective for enhancing the antitumor activity of antitumor agents because it can enhance sensitivity of tumor cells to antitumor agents regardless the tumor cells have resistance to the antitumor agents or not.

Agent for enhancing antitumor activity of antitumor agent

Growing community of inventors

Tokyo, Japan

Takashi Tsuruo